Read our Recent Headlines


Jun 23, 2017 by Dave Sobek

June 23 Biotech Update

We are finally getting a break in the move higher but it has been quiet impressive. There was less excitement in the move than I would have thought, which I.

Share 2 comments Read more
Jun 22, 2017 by Dave Sobek

June 22 Biotech Update

The sector continues to rocket higher as clearly sentiment has reversed. This run likely has more legs than anyone thinks. The sector has been in a massive bear market and.

Jun 21, 2017 by Dave Sobek

June 21 Biotech Update

Biotech is clearly back. We appear to be breaking out of the range with perhaps broadening participation and increasing volume. I am not a technician but this is looking good..

Jun 20, 2017 by Dave Sobek

June 20 Biotech Update

The sector seems to be breaking out of its range with another early show of strength. While it is still early and we have been here before, the background seems.

Jun 19, 2017 by Dave Sobek

June 19 Biotech Update

The sector finally does not have bad news this morning to undercut any momentum. We are still waiting on the M&A cycle to start but at this point I do.

Jun 16, 2017 by Jason DeLorenzo

Dave Trading – July 2017

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

Jun 15, 2017 by Dave Sobek

June 15 Biotech Update

The market is certainly continuing its recent weakness (especially NASDAQ) but today biotech is down with it. Is this the start of another move to the lower end of its.

More From All Reports

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More